Sertindole: efficacy and safety in schizophrenia

Bibliography

• WIDERLÖV B, BORGÅ P, CULLBERG J, STEFANSSON C-G, LINDQVIST G: Epidemiology of long-term functional psychosis in three different areas in Stockholm County. Acta Psychiatr. Scand. (1989) 80:40-46.
   PubMed Web of Science ®Google Scholar
• WIDERLÖV B: Långvarig funktionell psykos-epidemuiologi, vårduttnyttjande och sociala förhållanden i tre demografiskt skilda områden. [Long-term functional psychosis – epidemiology, need of care and social circumstanses in three different demographic areas. Master exam in social work]. Licenciatuppsats i socialt arbete (1990).
   Google Scholar
• MCGRATH JJ: Variations in the incidence of schizophrenia: data versus dogma. Schizophr. Bull. (2006) 32:195-197.
   PubMed Web of Science ®Google Scholar
• LINDSTRÖM E, WIDERLÖV B, VON KNORRING L: The ICD-10 and DSM-IV diagnostic critera and the prevalence of schizophrenia. Eur Psychiatry (1997) 12:217-223.
   Web of Science ®Google Scholar
• WIESELGREN I-M: Prognosis and early prognostic factors in schizophrenia. Thesis. Uppsala University (1995).
   Google Scholar
• GOVERNMENTAL COMMITTEE OF PSYCHIATRY: Welfare and free choice: Stockholm. Allmänna förlaget (1992):73.
   Google Scholar
• LECOMTE P, DE HERT M, VAN DIJK M, NUIJTEN M, NUYTS G, PERSSON U: A 1-year cost-effectiveness model for the treatment of chronic schizophrenia with acute exacerbation in Belgium. Value Health (2000) 3(1):1-11.
   PubMedGoogle Scholar
• CHUE PS, HEEG B, BUSKENS E, VAN HOUT BA: Modelling the impact of complience on the costs and effects of long-acting risperidone in Canada. Pharmacoeconomics (2005) 23(Suppl. 1):62-74.
   PubMed Web of Science ®Google Scholar
• LINDSTRÖM E: The hidden costs of schizophrenia. J. Drug Dev. Clin. Pract. (1996) 7:281-288.
   Google Scholar
• BROWN CS, MARKOWITZ JS, MOORE TR et al.: Atypical antipsychotics (Pt II): adverse effects, drug interactions, and costs. Ann. Pharmacother. (1999) 33(2):210-217.
   PubMed Web of Science ®Google Scholar
• NABER D, LAMBERT M: Sertindole decreases hospitalization and improves the quality of life of schizophrenic patients. Int. J. Psychiatry Clin. Pract. (1998) 2(Suppl. 2):73-77.
   Google Scholar
• DELAY J, DENIKER P: Methodes chimiotherapiques en psychiatrie. Masson et Cie, Paris (1961).
   Google Scholar
• LUBLIN H, EBERHARD J, LEVANDER S: Current therapy issues and unmet clinical needs in the treatment of schizophrenia: a review of the new generation antipsychotics. Int. Clin. Psychopharmacol. (2005) 20:183-198
   PubMed Web of Science ®Google Scholar
• MOREL: Traite des maladies mentales (1860).
   Google Scholar
• KRAEPELIN E: Dementia Praecox and paraphrenia. Krieger, New York (1919).
   Google Scholar
• BLEULER E: Dementia Praecox oder die Gruppe der Schizophrenien. Leipzig-Wein: Aschaffenburgs Handbuch der Psychiiatrie, 1911. Translated into English by H Zinkin: Dementia Praecox or the Group of Schizophrenias. International New York, Universities Press, 1950.
   Google Scholar
• SCHNEIDER K: Klinische Psychopathologie. Translated by MW Hamilton. Grune and Statton, New York (1959).
   Google Scholar
• MAYER-GROSS W: In: Handbuch der Geisteskrankheiten 10. Bumke O (Ed). Springer-Verlag (1932).
   Google Scholar
• KAY SR, SEVY S: Pyramidacal model of schizophrenia. Schizophr. Bull. (1990) 16:537-544.
   PubMed Web of Science ®Google Scholar
• BELL MD, LYSAKER PH, BEAM-GOULET JL, MILSTEIN RM, LINDENMAYER JP: Five-component model of schizophrenia: assessing the factorial invariance of the positive and negative syndrome scale. Psychiatry Res. (1994) 52(3):295-303.
   PubMed Web of Science ®Google Scholar
• LINDENMAYER JP, BERNSTEIN-HYMAN R, GROCHOWSKI SP: Five-factor model of schizophrenia. Initial validation. J. Nerv. Ment. Dis. (1994) 182(11):631-638.
   PubMed Web of Science ®Google Scholar
• GREEN MF: What are the functional consequences of neurocognitive deficits in schizophrenia? Am. J. Psychiatry (1996) 153:321-330.
   PubMed Web of Science ®Google Scholar
• KANE J, HONIGFELD G, SINGER J, MELTZER H AND THE CLOZARIL COLLABORATIVE STUDY GROUP: Clozapine for the treatment-resistant schizophrenic: a double-blind camparison with chlorpromazine. Arch. Gen. Psych. (1988) 45:789-796.
   PubMed Web of Science ®Google Scholar
• BUCHANAN RW, BREIER A, KIRKPATRICK B, BALL P, CARPENTER WT Jr: Positive and negative symptome response to clozapine in schizophrenic patients with and without the deficit syndrome. Am. J. Psychiatry (1998) 155:751-760.
   PubMed Web of Science ®Google Scholar
• LIEBERMAN JA, STROUP TS, MCEVOY JP et al.: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. (2005) 353:1209-1223.
   PubMed Web of Science ®Google Scholar
• LINDSTRÖM E, EBERHARD J, LEVANDER S: Five years follow-up during antipsychotic treatment: efficacy, safety and social outcome. Acta Psychiatr. Scand. (submitted).
   Google Scholar
• HEATON RK, CROWLEY TJ: Effects of psychiatric disorders and their somatic treatment on neuropsychological test results. In: Handbook of Clinical Neuropsychology. Filskov SB Boll TJ (Eds) Wiley Press, New York (YEAR):481-525.
   Google Scholar
• MEDALIA A, GOLD JM, MERRIAM A: The effects of neuroleptics on neuropsychological test results of schziophrenics. Arch. Clin. Neuropsychol. (1988) 3:249-271.
   PubMedGoogle Scholar
• SPOHN HE, STRAUSS ME: Relation of neuroleptic and anticholinergic medication to cognitive functions in schizophrenics. J. Abnorm. Psychol. (1989) 98:367-380.
   PubMed Web of Science ®Google Scholar
• CASSENS G, INGLIS AK, APPELBAUM PS, GUTHEIL TG: Neuroleptics: effects on neuropsychological function in chronic schizophrenic patients. Schizophrenia Bull (1990) 16:477-499.
   PubMed Web of Science ®Google Scholar
• KING DJ: The effcet of neuroleptics on cognitive and psychomotor function. Br. J. Psychirty (1990) 157:799-811.
   PubMed Web of Science ®Google Scholar
• BILDER RM, TURKEL E, LIPSCHULTZ-BROCH L, LIEBERMAN JA: Antipsychotic medication effects on neuropsychological functions. Psychophamacol. Bull. (1992) 28:353-366.
   PubMedGoogle Scholar
• GRÅWE RW, LEVANDER S: Smooth pursuit eye movements and neuropsychological impairments in schizophrenia. Acta Psychiatr. Scand. (1995) 92:108-114.
   PubMedGoogle Scholar
• GREEN MF, NUECHTERLINE KH et al.: Approaching a consensus cognitive battery for clinical trials in schizophrenia. Biol. Psychiatry (2004) 56:301-307.
   PubMed Web of Science ®Google Scholar
• LEVANDER S: Central cognitive deficits in schizophrenia. In: Cognition and schizophrenia: improving real life function. Morgan K, Murray R et al. (Eds). Cambridge University Press (2006).
   Google Scholar
• LEUCHT S, WAHLBECK K, HAMANN J, KISSLING W: New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and metaanalysis. Lancet (2003) 362(9381):404; author reply 404-405.
   Google Scholar
• EBERHARD J, LINDSTRÖM E, LEVANDER S: Tardive dyskinesia and neuroleptics – a 5-year longitudinal study of frequency, correlates and course. Int. Clin. Psychopharmacol. (2006) 21(1):35-42.
   PubMedGoogle Scholar
• KLAWANS HL: The psychopharmacology of tardive dyskinesia. Am. J. Psychiatry (1973) 130:82-86.
   PubMedGoogle Scholar
• GERLACH J, CASEY DE: Tardive dyskinesia. Acta Psychiatr. Scand. (1988) 77(4):369-378.
   PubMed Web of Science ®Google Scholar
• LIEBERMAN JA, SALTZ BL, JOHNS CA, POOACL S, BORENSTEIN M, KANE J: The effects of clozapine on tardive dyskinesia. Br. J. Psychiatry (1991) 158:503-510.
   PubMed Web of Science ®Google Scholar
• TAMMINGA CA, THAKER GK, MORAN M, KAKIGI T, GAO XM: Clozapine in tardive dyskinesia: observations from human and animal models. J. Clin. Psychiatry (1994) 55(Suppl.):102-106.
   PubMed Web of Science ®Google Scholar
• SPIVAK B, MESTER R, ABESGAUS J et al.: Clozapine treatment for neuroleptic-indiced tardive dyskinesia, parkinsonism, and chronic akathisia in schizophrenic patients. J. Clin. Psychiatry (1997) 58(7):318-322.
   PubMedGoogle Scholar
• EMSLEY R, TURNER HJ, SCHRONEN J, BOTHA K, SMIT R, OOSTHUIZEN PP: A single-blind, randomized clinical trial comparing quetiapine and haloperidole in the treatment of tardive dyskinesia. J. Clin. Psychiatry (2004) 65(5):696-701.
   PubMed Web of Science ®Google Scholar
• PERQUIN L: Treatment with sertindole for late-occuring undesirable movements. Int. Clin. Psychopharmacol. (submitted).
   Google Scholar
• TUNE LE, STRAUSS ME, LEW MF, BREITLINGER E, COYLE JT: Serumlevels of anticholinergic drugs and impaired recent memory in chronic schizophrenic patients. Am. J. Psychiatry (1982) 139:1460-1462.
   PubMed Web of Science ®Google Scholar
• MOORE N: Higher cardiovascular mortality with sertindole in ADROIT: a signal not confirmed. Int. J. Psychiatry Clin. Pract (2002) 6 Suppl. 1:3-9.
   Google Scholar
• RAGGI MA, MANDRIOLI R, SABBIONI C, PUCCI V: Atypical antipsychotics: pharmacokinetics, therapeutic drug monitoring and pharmacological interaction. Curr. Med. Chem. (2004) 11(3):279-296.
   Google Scholar
• ANDREWS G, HALL W, GOLDSTEIN G: The economic costs of schizophrenia. Implications for public policy. Arch. Gen. Psychiatry (1985) 42:537-543.
   PubMed Web of Science ®Google Scholar
• RICE DP, KELMAN S, MILLER LS: The economic costs of alcohol and drug abuse and mental illness. National Institute of Mental Health. Rockville, MD (1990).
   Google Scholar
• DAVIES LM, DRUMMOND MF: Economics and schizophrenia: the real cost. Br. J. Psychiatry Suppl. (1994) 165(Suppl. 25):18-21.
   Google Scholar
• EUROPEAN PARLIAMENT SESSION DOCUMENTS: Reports of the Committee on Energy, Research and Technology. Seligman M (1992).
   Google Scholar
• LINDSTRÖM E, EBERHARD J, MILESSON FORS B, HANSEN K, SAPIN C, LAUNOIS R: A pharmacoeconomic analysis of schizophrenia management in Sweden. Abstract. Presented at the 14th European Congress of Psychiatry. Nice, France (2006).
   Google Scholar
• LEWIS R, BAGNALL AM, LEITNER M: Sertindole for schizophrenia. Cochrane Database Syst Rev (2005) 20(3):CD001715.
   Google Scholar
• AZORIN J-M, STRUB N, LOFT H: A double-blind, controlled study of sertindole versus risperidone in the treatment of moderate-to-severe schizophrenia. Int. Clin. Psychopharmacol. (2006) 21:49-56.
   PubMed Web of Science ®Google Scholar
• KONGSAMUT S, KANG J, CHEN XL, ROEHR J, RAMPE D: A comparison of the receptor binding and HERG channel affinities for a series of antipsychotic drugs. Eur. J. Pharmacol. (2002) 450(1):37-41
   PubMed Web of Science ®Google Scholar
• HADDAD PM, ANDERSON IM: Antipsychotic-related QTc prolongation, torsade de pointes and sudden death. Drugs (2002) 62(11):1649-1671.
   PubMed Web of Science ®Google Scholar
• LINDSTRÖM E, ERIKSSON L, LEVANDER S: Suicide in psychosis. Nordic Journal of Psychiatry (submitted).
   Google Scholar
• NORDSTRÖM A, DAHLGREN L, KULLGREN G: Victim reltions and factors triggering homicides committed by offenders with schizophrenia. Acta Psychiatr. Scand. (submitted).
   Google Scholar
• NEOVIUS M, EBERHARD J, LINDSTRÖM E, LEVANDER S: Weight development in patients treated with risperidone snd other antipsychotics: a five-year naturalistic study. Acta Psychiatr. Scand. (submitted).
   Google Scholar
• EBERHARD J, LINDSTRÖM E, HOLSTAD M, LEVANDER S: Prolactin response to treatment with risperidone and risperidone combined with other psychotropic drugs in patients with schizophrenia and other psychotic disorders. Acta Psychiatr. Scand. (In press).
   Google Scholar
• PERQUIN L, STEINERT T: A review of the efficacy, tolerability and safety of sertindole in clinical trials. CNS Drugs (2004) 18(Suppl. 2):19-30.
   PubMed Web of Science ®Google Scholar
• ARNT J, SKARSFELDT T: Do novel antopsychotics have the similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology (1998) 18:63-101.
   PubMed Web of Science ®Google Scholar
• HERRICK-DAVIS K, GRINDE E, TEITLER M: Inverse agonist activity of atypical antipsychotic drugs at human 5-hydroxy-tryptamine2Creceptors. J. Pharmacol. Exp. Ther. (2000) 295(1):226-232.
   PubMed Web of Science ®Google Scholar
• HIETALA J, KOUPPOAMÄKI M, MAJASUO H et al.: Sertindole is a serotonin 5-HT2C inverse agonist and decreases agonist but not antagonist binding to 5-HT2C receptors after chronic treatment. Psychopharmacology (2001) 157(2):180-187.
   PubMed Web of Science ®Google Scholar
• KASPER S, TAUSHER J, KUFFERLEE B: Sertindole and dopamine D2 receptor occupancy in comparison to risperidone, clozapine, and haloperidole: a 123I-IBZM SPECT study. Psychopharmacology (1998) 136:367-373.
   PubMed Web of Science ®Google Scholar
• PILOWSKY LS, O´CONELL P, DAVIES N et al.: In vivo effects on striatal dopamine D2 receptor binding by the novel atypical antipsychotic drug sertindole: a 123I IBZM single photon emission tomography (SPET) study. Psychopharmacol. (1997) 130:152-158.
   PubMed Web of Science ®Google Scholar
• ZIPURSKY RB, CHRISTENSEN BK, DASKALAKIS Z et al.: Treatment response to olanzapine and haloperidol and its association with dopamine D receptor occupancy in first-episode psychosis. Can. J. Psychiatry (2005) 50(8):462-469.
   PubMedGoogle Scholar
• LINDSTRÖM E, FARDE L, EBERHARD J, HAVERKAMP W: QTc interval prolongation and antipsychotic drug treatment: focus on sertindole. Int. J. Neuropsychopharmacol. (2005) 8:615-629.
   PubMed Web of Science ®Google Scholar
• HAVERKAMP W, ECKARDT L, MATZ J: Sertindole: cardiac electropsysiological profile. Int. J. Psychiatry Clin. Pract. (2002) 6(Suppl. 1):11-20.
   PubMed Web of Science ®Google Scholar
• THOMSEN MB, VOLDERS PGA, STENGL M et al.: Electrophysiological safety of sertindole in dogs with normal and remodelled hearts. J. Pharmacol. Exp. Ther. (2003) 307(2):776-784.
   PubMed Web of Science ®Google Scholar
• WONG SL, SEBREE T, GRANNEMAN GR: Dose-proportionality of sertindole after 4-16 mg single-dose oral administration (abstact no. PPDM 8438). Pharm. Res. (1996) 13(9 Suppl.):502.
   Google Scholar
• WONG SL, LINNEN P, MACK R et al.: Effects of food, antacid, and dosage form on the pharmacokinetics and relative bioavailability of sertindole on healthy volonteers. Biopharm. Drug Dispos. (1997) 18(6):533-541.
   PubMed Web of Science ®Google Scholar
• WONG SL, CAO G, MACK RJ et al.: Pharmacokinetics of sertindole in healthy young and elderly male and female subjects. Clin. Pharmacol. Ther. (1997) 62(2):157-164.
   PubMed Web of Science ®Google Scholar
• WONG SL, MENACHERRY S, MULFORD D et al.: Pharmacokinetics of sertindole and dehydrosertindole in volunteers with normal or impaired renal function. Eur. J. Clin. Pharmacol. (1997) 52:223-227.
   PubMed Web of Science ®Google Scholar
• MARKOWITZ JS, BROWN CS, MOORE TR: Atypical antipsychotics. Part 1: pharmacology, pharmacokinetics, and efficacy. Ann. Pharmacother. (1999) 33(1):73-85.
   PubMed Web of Science ®Google Scholar
• KANE JM, TAMMINGA CA: Sertindole (Serdolect): preclinical and clinical findings of a new atypical antipsychotic. Expert Opin. Invest. Drugs (1999) 6(11):1729-1741.
   Google Scholar
• KAY SR: The positive and negative syndrome scale for schizophrenia (PANSS). Schizophrenia Bull (1987) 13:261-276.
   PubMed Web of Science ®Google Scholar
• VAN KAMMEN DP, MCEVOY JP, TARGUM SD et al.: A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia. Psychopharmacology (1996) 124(1-2):168-175.
   PubMed Web of Science ®Google Scholar
• ZIMBROFF DL, KANE JM, TAMMINGA CA et al.: Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Am. J. Psychiatry (1997) 154(6):782-791.
   PubMed Web of Science ®Google Scholar
• HALE A, AZORIN J-M, KASPER S et al.: Sertindole improves both the negative and positive symptoms of schizophrenia: results from a Phase III trial. Int. J. Psychiatry Clin. Pract. (2000) 4:55-62.
   PubMed Web of Science ®Google Scholar
• DANIEL DG, WOZNIAK P, MACK RJ et al.: Long term efficacy and safety comparison of sertindole and haloperidol in the treatment of schizophrenia. Psychopharmacol. Bull. (1998) 34(1):61-69.
   PubMed Web of Science ®Google Scholar
• KANE JM, POTKIN S, BUCKLEY P: Safety and efficacy of sertindole and risperidone in treatment of resistant patients with schizophrenia (abstact and poster). 10th International Congress on Schizophrenia Research. Savannah, GA (2005).
   Google Scholar
• SCHUCK P, VAN DEN AMEELE H, JAANSON P, RYCKMANS V, HAWLEY C: Case histories illustating the utility of sertindole in clinical practice. CNS Drugs (2004) 18(Suppl. 2):31-43.
   PubMed Web of Science ®Google Scholar
• BROWN S: Excess mortality of schizophrenia. A meta-analysis. Br. J. Psychiatry (1997) 171:502-508.
   PubMed Web of Science ®Google Scholar
• HARRIS EC, BARRACLOUGH B: Suicide as an outcome for mental disorders. A meta-analysis. Br. J. Psychiatry (1997) 170:205-228.
   PubMed Web of Science ®Google Scholar